Outdated criteria for drug plan reimbursement obstruct evidence-based care

[See related articles at [www.cmaj.ca/lookup/doi/10.1503/cmaj.210523][2]][2] and [[www.cmaj.ca/lookup/doi/10.1503/cmaj.210811][3]][3] An important flaw in the funding approach used by Canada’s public drug plans is highlighted by the findings of 2 articles related to the clinical value of direct